

Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.610, 2010-01, pp. : 8-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Could a patient-based formula guide funding allocation in the UK?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 643, 2011-01 ,pp. :


PharmacoEconomics and Outcomes News, Vol. 1, Iss. 448, 2004-01 ,pp. :




Access to experimental drugs: a constitutional right or false hope?
Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. :


Co-proxamol dangerous in overdose: should access be restricted?
Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. :